Medicover Genetics recently launched a plasma-based test for longitudinal minimal residual disease monitoring in patients with unresectable non-small cell lung cancer (NSCLC) at ESMO 2026 in Madrid. Details of OncoSentia MRD are reported in a press release.

OncoSentia MRD will be offered as a centralized laboratory service through Medicover Genetics’ CAP-accredited, CLIA-certified laboratories, serving healthcare providers across European markets. The test's clinical focus is on patients with unresectable Stage II or III NSCLC following definitive treatment, including during consolidation therapy and post-treatment surveillance. Supporting clinical validation evidence is derived from the DART clinical trial.

OncoSentia MRD uses a tumor-agnostic, plasma-informed workflow to analyze circulating tumor DNA (ctDNA) without requiring prior tumor-tissue profiling. Molecular signals identified in plasma inform patient-specific ctDNA detection.

Supporting evidence comes from the prospective, multicenter DART study of patients with unresectable stage III NSCLC treated with chemoradiotherapy followed by durvalumab. The published analysis included 659 plasma samples from 84 patients, collected across multiple treatment and follow-up time points.

ctDNA detected during consolidation treatment and surveillance was significantly associated with poorer progression-free survival. In a multivariable, time-dependent analysis of post-chemoradiotherapy samples, detectable ctDNA was associated with a nearly threefold higher risk of progression (HR 2.95; 95% CI 1.69–5.15). When evaluating specific clinically relevant timepoints, ctDNA positivity midway through consolidation was associated with 2.45-fold higher risk for progression (HR 2.45; 95% CI 1.18-5.11) while an even greater risk is shown for patients who are tested positive 3 months post-consolidation (HR 5.37; 95%CI 1.93-14.93).

Among patients who progressed and had detectable ctDNA, ctDNA detection preceded radiological or clinical progression by a median of 7.4 months. Together, these findings support the prognostic relevance of longitudinal ctDNA monitoring across clinically relevant time points and its potential to provide additional molecular insights alongside established clinical and imaging surveillance.

Visit Medicover Genetics for more news